{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:08:29Z","timestamp":1791382109624,"version":"4.3.3"},"reference-count":37,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>Lutetium\u2010177 (Lu\u2010177) prostate\u2010specific membrane antigen radioligand therapy (PSMA\u2010RLT) is a promising therapy for metastatic castration\u2010resistant prostate cancer (mCRPC), but there is limited data of its efficacy and safety in Asian population. We aim to explore the clinical outcomes of Lu\u2010177 PSMA\u2010RLT in this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We evaluated 84 patients with progressive mCRPC receiving Lu\u2010177 PSMA\u2010RLT between 9 May 2018 and 21 February 2022. Lu\u2010177\u2010PSMA\u2010I&amp;T was administered at 6\u20138\u2010week intervals. Primary end point was overall survival (OS), and secondary end points included prostate\u2010specific antigen (PSA) progression\u2010free survival (PFS), PSA response rate, clinical response, toxicity assessment, and prognostic indicators.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median OS and PSA PFS were 12.2 and 5.2 months, respectively. PSA decline of \u226550% was observed in 51.8% of patients. Patients achieving PSA response had longer median OS (15.0 vs. 9.5 months, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.03) and PSA PFS (6.5 vs. 2.9 months, <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.001). Pain score improvement was seen in 19 out of 34 patients. A hematotoxicity of \u2265grade 3 was observed in 13 out of 78 patients. Multivariable analyses showed that PSA velocity, alkaline phosphatase, hemoglobin (Hb), and the number of treatment cycles were independent prognostic indicators for OS. The retrospective design was the main limitation of the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study demonstrated a similar safety and efficacy of Lu\u2010177 PSMA\u2010RLT in Asian mCRPC patients compared to the existing literature. A PSA decline \u226550% was associated with longer OS and PSA PFS. Several prognostic indicators for patient outcomes were also identified.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.13944","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T07:39:51Z","timestamp":1680248391000},"page":"572-581","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Outcomes and prognostic predictors of Lu\u2010177 PSMA radioligand therapy in metastatic castration\u2010resistant prostate cancer (Asian Population Study)"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2021-3586","authenticated-orcid":false,"given":"Wei Ming","family":"Chua","sequence":"first","affiliation":[{"name":"Division of Radiological Sciences Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie Wing\u2010Chuen","family":"Lam","sequence":"additional","affiliation":[{"name":"Division of Radiological Sciences Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital  Singapore Singapore"},{"name":"Radiological Sciences Academic Clinical Program SingHealth Duke\u2010NUS Academic Medical Centre  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron Kian\u2010Ti","family":"Tong","sequence":"additional","affiliation":[{"name":"Division of Radiological Sciences Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital  Singapore Singapore"},{"name":"Radiological Sciences Academic Clinical Program SingHealth Duke\u2010NUS Academic Medical Centre  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehena","family":"Sultana","sequence":"additional","affiliation":[{"name":"Duke\u2010NUS Graduate Medical School  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Mei Yu","family":"Kua","sequence":"additional","affiliation":[{"name":"Division of Radiological Sciences Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindran","family":"Kanesvaran","sequence":"additional","affiliation":[{"name":"Duke\u2010NUS Graduate Medical School  Singapore Singapore"},{"name":"Department of Medical Oncology National Cancer Centre  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin Seng Cheong","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010Oncology National University Cancer Institute  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kae Jack","family":"Tay","sequence":"additional","affiliation":[{"name":"Duke\u2010NUS Graduate Medical School  Singapore Singapore"},{"name":"Department of Urology Singapore General Hospital  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai Jit Lenith","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging National University Hospital  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Chee Eng","family":"Ng","sequence":"additional","affiliation":[{"name":"Division of Radiological Sciences Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital  Singapore Singapore"},{"name":"Radiological Sciences Academic Clinical Program SingHealth Duke\u2010NUS Academic Medical Centre  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue Ping","family":"Thang","sequence":"additional","affiliation":[{"name":"Division of Radiological Sciences Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital  Singapore Singapore"},{"name":"Radiological Sciences Academic Clinical Program SingHealth Duke\u2010NUS Academic Medical Centre  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.03.028"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1701695"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.01.001"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.722277"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010020\u201004934\u20104"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2019.07.003"},{"key":"e_1_2_6_9_1","unstructured":"SchaefferEM SrinivasS AnY et\u00a0al.NCCN clinical practice guidelines in oncology: prostate cancer. version 1.2023. Accessed 3 February 2023.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000001179"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)00237\u20103"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmrs.227"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"e_1_2_6_14_1","unstructured":"US Department of Health and Human Services.Common Terminology Criteria for Adverse Events. Version 5. Published November 27 2017. Available at:https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.224055"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523\u2010021\u201000801\u2010w"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.11.016"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236414"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.18.20845"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010020\u201004797\u20109"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.03.004"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21239054"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010021\u201005237\u2010y"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11061108"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23912"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010017\u20103848\u20104"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010020\u201005040\u20101"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(21)00274\u20106"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051078"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjmsu.2011.08.006"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv545"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010018\u20104222\u2010x"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020407"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13550\u2010021\u201000805\u20107"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.05.025"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030647"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T09:36:43Z","timestamp":1731836203000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/ajco.13944"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13944","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]},"assertion":[{"value":"2022-09-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}